Navigation Links
InterMune to Present at Citi's 4th Annual Biotech Day
Date:3/30/2009

BRISBANE, Calif., March 30 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at Citi's 4th Annual Biotech Day in New York City on April 1, 2009 at 10:40 a.m. EDT.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF, RECAP, an open-label extension study from CAPACITY, and a research program focused on pirfenidone analog ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
2. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
3. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
4. InterMune Announces Issuance of U.S. Patent for ITMN-191
5. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
6. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
7. InterMune to Present at J.P. Morgan Healthcare Conference
8. InterMune to Present at Deutsche Bank Biotech Boston Confab
9. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
10. InterMune to Release Third Quarter 2008 Financial Results on November 6
11. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... PALM BEACH, Fla. , July 11, 2014 /PRNewswire-iReach/ ... variety of high-quality peptides that are used solely in ... To honor two successful years in business, Maxim Peptide, ... LLC, has just launched a new and updated website ... the research blog section has been updated with fascinating ...
(Date:7/11/2014)... July 11, 2014 , Not for ... into or from any jurisdiction where to do so would ... Shire plc ("Shire" or the "Company") (LSE: SHP, ... afternoon.  Shire confirms it has held a meeting with representatives ... Shire without the prior agreement or approval of AbbVie. ...
(Date:7/11/2014)... July 11, 2014 Research and Markets ... Technology Market - Global Industry Analysis, Size, Share, Growth, ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... acids (either DNA or RNA) into cells. This technology ... cancer cells and protein metabolism by affecting the nuclear ...
(Date:7/11/2014)... July 11, 2014 BCC Research ( ... DIGITAL POLYMERASE CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , ... technology reached nearly $140 billion in 2013. This is ... a five-year compound annual growth rate (CAGR) of 28.6%. ... of interesting and exciting possibilities within the broader PCR ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Shire plc - Statement re: Media Speculation 2International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3
... 11 Amicus Therapeutics,(Nasdaq: FOLD ), today announced ... at the 5th Annual Lazard Capital Markets Healthcare,Conference in ... p.m. EST., A webcast and audio archive of ... at http://www.amicustherapeutics.com . Participants,should allow approximately five to ...
... a privately-held,biopharmaceutical company focused on developing novel cancer ... viral vector, today announced,that executive management will participate ... to be held November 10 through November 12,2008 ... York City. Frank D. Stonebanks,President and Chief Executive ...
... Calif., Nov. 11 Cord Blood,America, Inc. (OTC ... preservation company ( http://www.cordblood-america.com ) focused on,bringing the ... nationwide and,internationally, said today that the stem cell ... Obama intends to use his executive,authority to reverse ...
Cached Biology Technology:Cord Blood America Salutes President-Elect Obama's Promise to Lift Restrictions on Stem Cell Research 2
(Date:7/11/2014)... Wildlife Conservation Society shows that no-take zones in ... such as lobster, conch, and fish recover from ... areas. , The reporttitled "Review of the Benefits ... literature from no-take areas around the world. The ... recognized expert in marine protected areas and fisheries ...
(Date:7/11/2014)... 11, 2014--Researchers at the Department of Energy,s Oak ... awards, presented by R&D Magazine in recognition of ... awards recognize the tremendous value of our National ... and development at the National Labs continues to ... pursue the scientific and technological innovations necessary to ...
(Date:7/11/2014)... were many fires burning in eastern New South Wales, ... 11. , At 03:35 UTC on July 11 (12:35 ... Aqua passed over eastern New South Wales (NSW), the ... visible image of the region and spotted smoke (light ... MODIS,s thermal bands, are outlined in red. , The ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... OTO EXPO of the American Academy of Otolaryngology Head ... nose, and throat doctors in the world, will convene September ... 305 scientific research sessions, 594 posters, and several hundred instruction ... opportunity for journalists from around the world to cover breaking ...
... Carolina State University researcher has shown that water-gel-based solar ... cells to produce electricity. The findings prove the concept ... They also have the potential to be less expensive ... solar cells. The bendable devices are composed of ...
... determined that teenagers who have abortions are no more likely ... whose pregnancies do not end in abortion. The study ... California, San Francisco, is the first to use both depression ... of adolescents. The researchers found that young women in ...
Cached Biology News:2010 AAO-HNSF miniseminars: Sunday, Sept. 26, 2010 22010 AAO-HNSF miniseminars: Sunday, Sept. 26, 2010 3Mimicking nature, water-based 'artificial leaf' produces electricity 2National study: Abortion does not cause depression or low self-esteem in adolescents 2National study: Abortion does not cause depression or low self-esteem in adolescents 3
Mouse Anti-Amyloid beta [1-16], clone 6E10, Monoclonal Antibody...
The pCDF Expression System 1 plus Competent Cells contains 10 µg of pET-45b(+) DNA. pET-45b carries an N-terminal His•Tag ® coding sequence that is cleavable with enterokinase as well...
Nucleobindin 1 [NUCB1]...
Request Info...
Biology Products: